

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 13, 2016**

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-50761
(Commission File
Number)

11-3146460
(IRS Employer
Identification No.)

14 Plaza Drive Latham, New York
(Address of Principal Executive Offices)

12110
(Zip Code)

(518) 795-1400

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

Item 7.01 – Regulation FD Disclosure.

On January 13, 2016, Joseph M. DeVivo, President and Chief Executive Officer of AngioDynamics, Inc. (the "Company"), will present to certain investors at the JP Morgan 34th Annual Healthcare Conference. The conference slides are furnished herewith as Exhibit 99.1.

The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly reports on Form 10-Q for the fiscal periods ended August 31, 2015 and November 30, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit No.	Description
99.1	Presentation slides for the JP Morgan Healthcare Conference on January 13, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: January 13, 2016

By: /s/ Stephen A. Trowbridge
Stephen A. Trowbridge
Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.

Description

99.1

Presentation slides for the JP Morgan Healthcare Conference on January 13, 2016.



JP Morgan Healthcare Conference

Joseph M. DeVivo, President and CEO

January 13, 2016

ADVANCING CARE. REDUCING COMPLICATIONS. MINIMIZING COSTS.

Forward-Looking Statements

Notice Regarding Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly report on Form 10-Q for the fiscal period ended August 31, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

EmboMedics microsphere products have not been reviewed by the U.S. Food and Drug Administration or any other international regulatory body at this time; as such they are currently not available for sale by AngioDynamics.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported net sales excluding a supply agreement; adjusted sales growth; EBITDA (income before interest, taxes, depreciation and amortization); adjusted EBITDA; adjusted gross profit; adjusted net income and adjusted earnings per share. Additionally, this press release evaluates results on a constant currency basis. As a non-GAAP measure, constant currency excludes the impact of foreign currency exchange rate fluctuations. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

Profile of AngioDynamics

Global, leading provider of innovative, image-guided, minimally invasive solutions.

Founded: 1998
IPO: May 2004
ANGO (NASDAQ)

Employee Base:
1,300 employees
7 operating locations

Franchises:
Peripheral Vascular
Vascular Access
Oncology/Surgery


Global Footprint:
210+ global sales team in U.S., Australia, Canada, France,
Germany, Netherlands and U.K.
Present in 50+ markets through 110+ distributors



IR Heritage Drives Future Growth

In 1990, AngioDynamics began manufacturing diagnostic catheters to serve the emerging practice of the interventional radiologist. Every development since then has resulted from the company's commitment to serving interventional radiologists and their ability to offer minimally invasive, innovative treatment options to patients worldwide.

AngioDynamics will continue to leverage that legacy to enable future growth.



Our Strategic Foundation

Improve patient outcomes while lowering overall costs within the healthcare system and maximizing shareholder value

1

Invest in
growth drivers


2

Focus on R&D
to position for
future growth
opportunities

3

Transform
through
operational
excellence

Economic and Quality Measures





1

IMPROVING PATIENT OUTCOMES BY INVESTING IN GROWTH DRIVERS

Peripheral Vascular Overview

Thrombus Management



Venous Insufficiency



Fluid Management



Drainage



Angiographic Catheters





FY2015 Revenue: \$193 million

Clinical Unmet Need: VTE

VENOUS THROMBOEMBOLISM (VTE) INCIDENCE

Overall ~1 Million VTE Events per year in U.S.
 Overall 300,000 VTE Deaths per year in U.S. – #3 cause

**Additional:
 Annual Incidence**



Catheter/Lead RA
 200,000

RA Mass
 47,000

IVCF Thrombosis
 14,000

TV Endocarditis
 2,500

Current Treatment Options

Surgical Embolectomy

Mechanical / PharmacoMechanical

Oral Anticoagulation

Systemic and Catheter Directed Thrombolysis

Sources:

Heit JA, et al. *Blood*. 2005;106:267A.

Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012.




angiodynamics

The Thrombus Management Solution

A COMPREHENSIVE SOLUTION FOR VENOUS THROMBOEMBOLISM

ANGIOVAC

Designed for the removal of soft, fresh thrombi or emboli, AngioVac venous drainage system includes the Venous Drainage Cannula and the Extracorporeal Circuit



UNI*FUSE INFUSION CATHETER

Comprehensive line of catheter directed thrombolysis products offering increased flexibility for a wide array of clinical applications



Vascular Access Overview

PICC Lines



Ports




Dialysis



FY2015 Revenue: \$108 million

Clinical Need: Addressable PICC Complications



TREATING THE COMPLICATIONS CAUSED BY PICCs IS

6X

GREATER THAN THE TOTAL ACQUISITION COST OF THE DEVICE

* DVT cost was calculated on a mean DVT rate of 3.5%

** Assumption is single-dose efficacy

1. Evans S. et al. *Chest* (2013);143(3)

2. Deitcher SR, Fesen MR, Kiproff PM, et al. *J Clin Oncol*. 2002;20(1):317-324

3. Centers for Disease Control and Prevention (CDC). *MMWR Morb Mortal Wkly Rep*. 2011;60(8):243-248

4. Chopra V et al. *The American Journal of Medicine*. 2012; 125(8)

5. Maki, D. et al. *Mayo Clinic Proceedings*. 2006;81(9)



The BIOFLO Solution

A REVOLUTIONARY PICC TECHNOLOGY

NO HEPARIN

Minimizes complications associated w/ heparin

NO ANTIBIOTICS

Reduces risks associated w/ bacterial resistance


NOT A COATING

*Present throughout **entire** catheter*

NOT ELUTING

*Present for **life** of device*

UNLIKE OTHER TECHNOLOGIES THAT ARE SUPERFICIAL AND/OR TRANSIENT, THE BIOFLO MATERIAL IS DESIGNED TO BE PRESENT THROUGHOUT THE CATHETER AND PERMANENT



Coatings

(On the surface)




← Coating (Blue)

← Catheter Wall

Impregnated

(In the pores)




← Impregnated Agent (Gold)

← Catheter Wall

BioFlo Technology

(Throughout catheter material)



← Catheter Wall

Performance in Clinical Evaluations

FACILITY NAME	NUMBER OF PICCs PLACED	DVT REDUCTION
Academic Medical Center	1,251	85%
Community Hospital	533	25%
Community Hospital	1,212	36%
Hospital Group	252	79%
International Hospital	60	46%
Health System	3,891	32%
Academic Medical Center	52	55%
TOTAL	7,251	51%

FACILITY NAME	NUMBER OF PICCs PLACED	TPA REDUCTION
Children's Hospital	272	42%
Children's Hospital	477	62%
Community Hospital	533	75%
Community Hospital	1,212	62%
Hospital Group	252	73%
TOTAL	2,746	63%

**MORE THAN
8,000 BIOFLO
PICCs HAVE BEEN
EVALUATED**

**AVG REDUCTION
51% DVTs
63% tPA**

Data on file

Data was obtained during hospital product evaluations; several of these sites are working toward publications

Based on data collected at individual institutions; results may not be indicative of clinical experiences at other institutions




Opportunity: BioFlo for Contracted Business

5,686
Registered Acute
Care Hospitals

5,441
Acute Care Hospitals
Purchasing PICCs


The Market



4,872
Hospitals
Purchasing PICCs
under a GPO
Agreement

AngioDynamics

~30%
of ANGO Sales
are Contracted



GPO Contract History

of Hospitals that ANGO can officially sell PICCs through a GPO Contract



Opportunity: BioFlo Midline

NEW BIOFLO MARKET OPPORTUNITIES

Midline product is drawing not only from the current PICC market, but also from the peripheral IV market

CLINICAL ADVANTAGES

- 1. Ease of insertion for the clinician compared to other competitive devices*
- 2. Consistently, effectively draws blood over duration of the treatment*
- 3. Treat patients for the entire length of therapy*



Opportunity: Tip Location Services

Tip location, coupled with our innovative BioFlo Technology, will improve our competitive position in the PICC market



- ✓ **March 6, 2014:** Acquired regulatory control over Celerity platform and rights to next generation technology
- ✓ **Mid-summer 2014:** U.S. Clearance
- ✓ **Winter 2014/15:** U.S. No X-ray Clearance
- ✓ **Fall 2015:** EU No X-ray Clearance
- **Spring 2016:** Navigation
- **Fall 2017:** FireFly

Oncology / Surgery Overview


Non-Thermal Ablation



Microwave Ablation



Radiofrequency Ablation



Surgical Resection



FY2015 Revenue: \$52 million

Global Cancer Incidence

GLOBAL STATISTICS


Cancer is the leading cause of death worldwide¹

14 million new cases of cancer each year¹

8.2 million cancer-related deaths in 2012¹
and has not changed in over 50 years²

TREATMENT OPTIONS

- Surgical Ablation
- Radiotherapy
- chemotherapy
- Palliative Treatment



Most Common Causes of Cancer Death¹

AngioDynamics Leadership in Surgical Ablation

AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients.

THERMAL






NON-THERMAL



Radiofrequency

Microwave

IRE



The NanoKnife Solution

A REVOLUTIONARY SURGICAL TECHNOLOGY

A new treatment modality for locally advanced pancreatic and hepatic tumors


NOVEL TECHNOLOGY FOR THE ABLATION OF SOFT TISSUE

- Series of short, low energy direct current electrical pulses
- Does not rely on heat to ablate tissue
- Creates defects (pores) in cell membranes
- Cell death occurs by apoptosis
- This immune mediated cell death allows cellular clearance of debris and creates minimal tissue distortion




In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. In the United States, the NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition.

Building Clinical Evidence for NanoKnife



Mounting Clinical Data

More than 150 peer reviewed articles published



Opportunity: Asia-Pacific

China
Annual Cancer
Mortality:
9.8 million¹

Japan
Annual Cancer
Mortality:
1.9 million²

NanoKnife under review:

Taiwan
Thailand
Singapore
Malaysia

1. http://www.who.int/cancer/country-profiles/chn_en.pdf?ua=1
2. http://www.who.int/cancer/country-profiles/jpn_en.pdf?ua=1



2 INVESTING IN THE NEXT GENERATION OF GROWTH

Strong Product Development Pipeline*

PV

Inflation Device	FY16
Drainage Line Extension	FY16
AngioVac Line Extension	FY16
Non-Vascular Introducer	FY16
Pain-Free Laser Procedure	FY17
New Thrombus Management Product	FY17
Fluid Management Line Extension	FY17

VA

Celerity Navigation	FY16
BioFlo Port Line Extension	FY16
BioFlo PICC Line Extension	FY16
FireFly Tip Location	FY18
Next Generation BioFlo Port	FY18
Next Generation BioFlo PICC	FY18

O/S

Next Generation Microwave Ablation	FY17
NanoKnife Single Insertion Device	FY17
Next Generation NanoKnife System	FY18



3 TRANSFORM THROUGH OPERATIONAL EXCELLENCE

Operational Improvements Plan and Impact

Phase 1 - COMPLETE	Phase 2 - EXECUTING	Phase 3 - PLANNING
<ul style="list-style-type: none"> ✓ Implement near-term product family consolidation/elimination opportunities ✓ Target indirect procurement supplier consolidation and processes ✓ Compress Queensbury shift structure through deployment of Operational Excellence and Capex ✓ Re-align manufacturing organizational leadership 	<p>Site consolidation:</p> <ul style="list-style-type: none"> ✓ • Queensbury repurposed as Distribution Center for NY region □ • Products moved from Queensbury to Glens Falls □ Comprehensive product family consolidation □ Direct procurement consolidation 	<ul style="list-style-type: none"> □ Global distribution strategy □ Assess global manufacturing footprint □ Selective off shoring - e.g., Costa Rica, Malaysia, Singapore

In Process

Operational Excellence Net Savings Per Year (\$M)



Q2 Summary Financial Performance

<i>\$ in millions, except per share</i>	Q2 FY2016	Q2 FY2015	% Change	% Change FX Adjusted
Net sales	\$89.2	\$92.1	-3%	-1%(b)
GAAP Earnings per share (EPS)	\$(0.01)	\$0.04	-127%	-108%
Adjusted EPS^(a)	\$0.14	\$0.17	-19%	-15%
Free Cash Flow	\$9.2	\$(4.6)	-	-

FDA lifts final warning letters for AngioDynamics

DECEMBER 3, 2015 BY BRAD PERRIELLO — LEAVE A COMMENT



AngioDynamics
of warning
letters se
The feder

Funding pact includes pause for medical device tax

DECEMBER 16, 2015 BY BRAD PERRIELLO — LEAVE A COMMENT



The \$1.6 trillion deal struck last night on government includes a provision that waives Obamacare's medical device tax.



Summary Financial Performance

\$ in millions, except per share amounts	Three months ended Nov 30, 2015		Six months ended Nov 30, 2015	
	Sales	YoY Growth	Sales	YoY Growth
WW	\$89.2	-3%	\$172.9	-4%
WW^(a)	\$90.2	-2%	\$174.9	-3%
PV	\$51.1	3%	\$98.2	1%
VA	\$25.0	-11%	\$49.7	-9%
O/S	\$12.4	-9%	\$23.7	-9%
US^(b)	\$71.4	-2%	\$140.4	-1%
Int'l	\$17.8	-6%	\$32.5	-12%
Int'l^(a)	\$18.8	-1%	\$34.4	-6%
	Q2 2016	YoY Growth		
Adjusted EBITDA^(c)	\$13.4	-16%		
Adjusted EPS^(c)	\$0.14	-19%		
Adjusted EPS^{(a)(c)}	\$0.15	-15%		

(a) Constant-currency basis

(b) Excludes impact of our supply agreement.

(c) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.



Balance Sheet and Cash Flow

<i>\$ in millions</i>	Nov 30, 2015	May 31, 2015
Cash & investments	\$20.6	\$20.1
Net working capital	\$91.5	\$90.3
Total assets	\$760.4	\$773.6
Total debt	\$133.9	\$137.7
Total stockholder's equity	\$547.6	\$545.0
<i>\$ in millions, except per share amounts</i>	3 months ended Nov 30, 2015	3 months ended Nov 30, 2014
Cash Flow from operations	\$9.6	\$(2.1)
Free Cash Flow	\$9.2	\$(4.6)

Adjusted Income Statement^(a)

<i>\$ in millions, except per share amounts</i>	Three months ended Nov 30, 2015	Three months ended Nov 30, 2014	Six months ended Nov 30, 2015	Six months ended Nov 30, 2014
Sales	\$89.2	\$92.1	\$172.9	\$179.5
Gross margins	51.4%	51.7%	51.5%	52.1%
Operating expenses	\$35.8	\$36.1	\$71.0	\$71.2
Operating income	\$10.0	\$11.6	\$18.0	\$22.3
Operating margin	11%	13%	10%	12%
Net Income (loss)	\$5.1	\$6.2	\$9.1	\$11.9
EPS	\$0.14	\$0.17	\$0.25	\$0.33
EBITDA	\$13.4	\$15.9	\$25.3	\$30.4

(a) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.

31



AngioDynamics Transformation

Investor Profile

- Major acquisitions – Navilyst (2012), Vortex Medical (2012), Microsulis (2013)
- Disruptive technology in PV, VA, and O/S markets with strong product pipeline
- Significant international opportunity
- Operational Excellence Program in place to drive margin expansion
- Emerging GPO presence

Fiscal Guidance*

\$ in millions, except per share amounts

	Q3	Full-Year
Sales ^(c)	\$84-\$87	\$353-\$359
Adjusted EPS ^(d)	\$0.10-\$0.14	\$0.59-\$0.63

Net Sales

	FY11	FY12	FY13	FY14	FY15
Net Sales	\$216M	\$222M	\$342M	\$354M	\$357M
Reported Growth	0%	3%	54%	4%	1%
Pro Forma	0%	3%	-1% ^(a)	4%	1%
Adjusted Growth	-	-	-	5% ^(b)	2% ^{(b)(c)}

(a) On a pro forma basis, prior year sales for AngioDynamics and Navilyst Medical were \$344.6 million

(b) Excludes impact of our supply agreement

(c) Constant-currency basis